Salvage chemotherapy with docetaxel and pegylated liposomal doxorubicin in pretreated patients with platinum- and taxane-sensitive ovarian cancer: a multicenter phase II trial of the Hellenic Oncology Research Group (HORG)

By Koinis Filippos   Polyzos Aristidis   Christopoulou Athina   Zafeiriou Zafeiris   Emmanouilidis Christos   Papadimitraki Elisavet   Kalykaki Antonia   Kalbakis Kostas   Samonis George   Georgoulias Vassilis  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 4, 2014-04 ,pp. : 819-825

Springer Publishing Company

Access to resources Recommend Favorite

Lack of Efficacy of 24-h Infusional Topotecan in Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Trial

By Markman M.   Blessing J.A.   DeGeest K.   Morgan M.   Look K.Y.   Herzog T.J.   Rose P.G.  

Gynecologic Oncology, Vol. 75, Iss. 3, 1999-12 ,pp. : 444-446

Elsevier

Access to resources Recommend Favorite

Heavily pretreated ovarian cancer patients treated by single-agent gemcitabine. A retrospective outcome comparison between platinum-sensitive and platinum-resistant patients

By Safra Tamar   Ron Ilan   Boaz Mona   Brenner Joseph   Grisaru Dan   Inbar Moshe   Hayat Henry   Menczer Joseph   Golan Abraham   Levy Tally  

Acta Oncologica, Vol. 45, Iss. 4, 2006-06 ,pp. : 463-468

Informa Healthcare

Access to resources Recommend Favorite

A phase II study to determine the efficacy and tolerability of intravenous ZD9331 in heavily pretreated patients with ovarian cancer

By Rader J.S.   Clarke-Pearson D.   Moore M.   Carson L.   Holloway R.   Kao M.-S.   Wiznitzer I.   Douglass E.C.  

Gynecologic Oncology, Vol. 91, Iss. 2, 2003-11 ,pp. : 318-325

Elsevier

Access to resources Recommend Favorite

Tamoxifen in Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Ancillary Report

By Markman M.   Iseminger K.A.   Hatch K.D.   Creasman W.T.   Barnes W.   Dubeshter B.  

Gynecologic Oncology, Vol. 62, Iss. 1, 1996-07 ,pp. : 4-6

Academic Press

Access to resources Recommend Favorite